NZ613265B2 - Orally dispersible tablet - Google Patents
Orally dispersible tablet Download PDFInfo
- Publication number
- NZ613265B2 NZ613265B2 NZ613265A NZ61326512A NZ613265B2 NZ 613265 B2 NZ613265 B2 NZ 613265B2 NZ 613265 A NZ613265 A NZ 613265A NZ 61326512 A NZ61326512 A NZ 61326512A NZ 613265 B2 NZ613265 B2 NZ 613265B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- preparation
- oral
- medicament
- administration
- give
- Prior art date
Links
- 239000007919 dispersible tablet Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 190
- 239000003814 drug Substances 0.000 claims abstract description 113
- 235000000346 sugar Nutrition 0.000 claims abstract description 55
- 206010004938 Bipolar disease Diseases 0.000 claims abstract description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000007884 disintegrant Substances 0.000 claims abstract description 24
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N Ramelteon Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 claims abstract description 7
- 239000007931 coated granule Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 64
- 239000008187 granular material Substances 0.000 claims description 37
- QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 28
- 229940080818 propionamide Drugs 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 23
- 239000011247 coating layer Substances 0.000 claims description 22
- 229940079593 drugs Drugs 0.000 claims description 21
- 230000000069 prophylaxis Effects 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000000873 masking Effects 0.000 claims description 14
- 210000004369 Blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 229940112822 Chewing Gum Drugs 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 2
- 229960001150 ramelteon Drugs 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 77
- 230000035492 administration Effects 0.000 description 69
- 239000003826 tablet Substances 0.000 description 62
- 239000000843 powder Substances 0.000 description 56
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 47
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 43
- 235000010355 mannitol Nutrition 0.000 description 43
- 230000036912 Bioavailability Effects 0.000 description 33
- 230000035514 bioavailability Effects 0.000 description 33
- 238000010521 absorption reaction Methods 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000011248 coating agent Substances 0.000 description 28
- 238000000576 coating method Methods 0.000 description 28
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 26
- 239000011812 mixed powder Substances 0.000 description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 21
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 21
- 239000008108 microcrystalline cellulose Substances 0.000 description 21
- 229940016286 microcrystalline cellulose Drugs 0.000 description 21
- 239000008213 purified water Substances 0.000 description 21
- 229960000913 Crospovidone Drugs 0.000 description 19
- 239000002552 dosage form Substances 0.000 description 19
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 19
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 19
- 229920000881 Modified starch Polymers 0.000 description 18
- 229920002261 Corn starch Polymers 0.000 description 17
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 15
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 14
- 239000008120 corn starch Substances 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 238000005507 spraying Methods 0.000 description 14
- 239000002207 metabolite Substances 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 229940083542 Sodium Drugs 0.000 description 11
- 229940091252 Sodium supplements Drugs 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 9
- 229950008138 Carmellose Drugs 0.000 description 9
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 9
- 229940032147 Starch Drugs 0.000 description 9
- 230000000996 additive Effects 0.000 description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 9
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- FBPFZTCFMRRESA-BXKVDMCESA-N L-mannitol Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO FBPFZTCFMRRESA-BXKVDMCESA-N 0.000 description 8
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 8
- 210000002200 Mouth Mucosa Anatomy 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
- 229920003258 poly(methylsilmethylene) Polymers 0.000 description 8
- -1 (S)- N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan yl)ethyl]propionamide Chemical compound 0.000 description 7
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 7
- 230000035533 AUC Effects 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229940117960 vanillin Drugs 0.000 description 7
- 235000012141 vanillin Nutrition 0.000 description 7
- 241001489705 Aquarius Species 0.000 description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 6
- 229960003438 Aspartame Drugs 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 6
- 244000024675 Eruca sativa Species 0.000 description 6
- 235000014755 Eruca sativa Nutrition 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N Iron(III) oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 6
- 239000000605 aspartame Substances 0.000 description 6
- 235000010357 aspartame Nutrition 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229910000460 iron oxide Inorganic materials 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 229910001929 titanium oxide Inorganic materials 0.000 description 6
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 229920001531 copovidone Polymers 0.000 description 5
- 239000008383 extra-granule composition Substances 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 5
- 238000004080 punching Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- 229960003987 Melatonin Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000029578 entry into host Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- YJYPHIXNFHFHND-UHFFFAOYSA-N Agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 3
- 241001147458 Dasheen mosaic virus Species 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960002629 agomelatine Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 230000036868 Blood Concentration Effects 0.000 description 2
- 229940046011 Buccal Tablet Drugs 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010012378 Depression Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- 229940009714 Erythritol Drugs 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 229920003114 HPC-L Polymers 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 description 2
- 229940041678 Oral Spray Drugs 0.000 description 2
- 229940088417 PRECIPITATED CALCIUM CARBONATE Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940098466 Sublingual Tablet Drugs 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 230000035591 circadian rhythms Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N Azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 108091005504 Cation channels Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- 229960004038 Fluvoxamine Drugs 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001419 Melatonin receptor family Human genes 0.000 description 1
- 108050009605 Melatonin receptor family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940028444 Muse Drugs 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 210000002850 Nasal Mucosa Anatomy 0.000 description 1
- 210000000826 Nictitating Membrane Anatomy 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000008299 Pinus lambertiana Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 230000036056 RATIO OF AUC Effects 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001458 anti-acid Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 230000003419 expectorant Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000017423 hawthorn Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000004050 mood stabilizer Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-UHFFFAOYSA-N γ-Cyclodextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO GDSRMADSINPKSL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Abstract
Provided are rapidly disintegrating orally dispersing preparations. The preparations comprise a disintegrant mixed with sugar or sugar alcohol coated granules comprising a medicament. The preparations can comprise (S)-N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno[5, 4-b]furan-8-yl)ethyl] propionamide (ramelteon) as the medicament. Further provided are uses of ramelteon in the treatment of bipolar disorder. elteon) as the medicament. Further provided are uses of ramelteon in the treatment of bipolar disorder.
Description
PCT/JPZOIZ/051279
DESCRIPTION
ORALLY DISPERSIBLE TABLET
Technical Field
The present invention relates to a preparation with
improved disintegration property, a ation with improved
bioavailability of medicament, production s f and
the like.
(Background of the Invention)
[0002]
Patent document 1 discloses a tablet ning sugar
alcohol or saccharide having an average particle size of 30 pm
or below, an active ingredient and a disintegrant, and a
production method of a tablet comprising compression g a
mixture containing sugar l or sugar having an average
particle size of 30 um or below, an active ingredient and a
disintegrant.
Patent document 2 discloses an orally dispersible solid
pharmaceutical composition of atine, which contains
agomelatine and granules of simultaneously—dried lactose and
starch;
Patent document 3 discloses an orally dispersible, coated
solid pharmaceutical composition of agomelatine, which
contains a central core or a central layer comprising
agomelatine and excipients allowing an orally dispersible
formulation to be obtained, and an orally dispersible coating.
However, patent documents 1 — 3 do not disclose
improvement of preparation characteristics such as
disintegration property and the like by enclosing components
such as masking agent, binder and the like that prevent
egration in es.
[Document List]
[patent documents]
patent document 1: WOl997/047287
patent document 2: JP-A-2005~523253 (US 2005 131071 A1)
patent document 3: JP—A—2007—182440 (US 2007 134331 A1)
RY OF THE INVENTION]
Problems to be Solved by the Invention
An object of the present ion is to provide a novel
formulation technique capable of improving disintegration
property. In addition, another object of the present invention
is to e a preparation useful as an orally rapidly
disintegrating preparation. Moreover, an object of the present
invention is to provide a preparation e of promoting
medicament absorption from the oral mucosa by rapid
disintegration after sublingual administration, and improving
the medicament bioavailability.
The objects of the invention should be read disjunctively with
the alternative object of providing the public with a useful
alternative.
Means of g the ms
The present inventors have conducted intensive studies in
an attempt to solve the entioned problems and found that
the disintegration property of a medicament can be improved and
the bioavailability thereof can also be improved by containing a
component that prevents disintegration (masking agent, binder
and the like) as a granulation component in granules, and
formulating the preparation after coating a e of the
granule with sugar or sugar alcohol, which resulted in the
completion of the present invention.
Accordingly, the present invention provides the following.
A rapidly disintegrating preparation comprising es
comprising a medicament coated with a coating layer containing
sugar or sugar alcohol; and a disintegrant
(hereinafter sometimes to be abbreviated as preparation [1], the
same for the following [2] to [18].
(Followed by page 2a)
The rapidly disintegrating preparation of the above—
mentioned [1], wherein the granules sing a medicament
further contains a binder.
(Followed by page 3)
PCT/320121051279
The rapidly disintegrating preparation of the above-
mentioned [1], wherein the es comprising a medicament
further contains a masking agent.
The rapidly disintegrating preparation of the above—
mentioned [1], wherein the granules comprising a medicament
r contains a solubilizer.
[4—1] The rapidly egrating preparation of any of the
above—mentioned [l] — [4], wherein the disintegration time is
not more than 30 sec.
[4—2] The rapidly disintegrating preparation of any of the
above~mentioned [l] — [4], wherein the disintegration time is
not more than 30 sec and the absolute hardness is not less
than 1.0 N/mmz.
The “rapidly disintegrating ation” of the t
invention is also superior as a preparation for allowing
absorption of a medicament from the oral mucosa. Specifically,
it is as described below.
The preparation of any of the above—mentioned [1] — [4],
which is for oral—mucosal absorption.
The preparation of the above—mentioned [5], wherein the
medicament is (S)-N—[2~(1,6,7,8—tetrahydr0-2H-indeno[5,4—
b]furan—B-yl)ethyl]propionamide (general name ramelteon;
after sometimes to be abbreviated as compound A).
[7] The preparation of the above-mentioned [5] or [6], which
is a tabletu
A method of producing a rapidly disintegrating preparation,
comprising a step of producing granules comprising a
ment,
a step of forming a coating layer containing sugar or sugar
alcohol on the obtained granules, and
a step of mixing the coated granules with a disintegrant and
g the mixture.
In addition to the mentioned preparation [6], the
W0 20121099260
present inventors have conducted intensive studies of a
preparation superior in the absorption of nd A from the
oral mucosa, and showing improved bioavailability thereof, and
complete the following invention.
[9] A preparation for oral—mucosal absorption comprising (S)—
N—[2-(1,6,7,8—tetrahydro—2H-indeno[5,4-b1furan—8—
yl)ethyl]propionamide as a medicament; which shows a higher
ratio of the medicament in an ged form and a metabolite
of the medicament (i.e., ment in unchanged
form/metabolite of the medicament) after transfer into blood
than that by oral administration.
A preparation for oral-mucosal absorption comprising (S)—
N-[2~(l,6,7,8—tetrahydro—2H—indeno[5,4—b]furan—8—
yl)ethyl]propionamide as a medicament; which shows a higher
ratio of the medicament in an unchanged form and a metabolite
of the medicament after er into blood than that by oral
administration, and a disintegration time of not more than 30
sec.
A preparation for ucosal absorption sing (S)—
N—[Z-(l,6,7,8—tetrahydro—2H—indeno[5,4—b]furan—S—
yl)ethyl]propionamide as a medicament; which shows a higher
ratio of the medicament in an unchanged form and a metabolite
of the medicament after transfer into blood than that by oral
administration, a disintegration time of not more than 30 sec,
and absolute hardness of not less than 1.0 N/HmF.
A preparation for oral—mucosal absorption comprising (S)-
N—[Z—(l,6,7,8~tetrahydro~2H—indeno[5,4-b]furan—8~
yl)ethyl]propionamide and a masking agent; which shows not
less than about 10—fold improved bioavailability of (S)~N—[2—
(1,6,7,8—tetrahydro-2H—indeno[5,4—b]furan—B—
yl)ethyl]propionamide, as compared to that by oral
administration.
A preparation for oral—mucosal tion comprising (S)—
N—[2-(1,6,7,8—tetrahydro-2H-indeno[5,4—b]furan
yl)ethyl]propionamide and a masking agent; which shows not
W0 20121099260 PCT/JPZOIZ/051279
less than about 10—fold improved bioavailability of [2—
(1,6,7,8—tetrahydro-2H—indeno[5,4—b]furan—S—
yl)ethyl]propionamide, as compared to that by oral
administration, and a disintegration time of not more than 30
sec.
A preparation for oral—mucosal absorption comprising (S)—
N—[2—(1,6,7,8—tetrahydro-2H—indeno[5,4—b]furan-8—
yl]propionamide and a masking agent; which shows not
less than about 10—fold improved bioavailability of (S)—N-[2-
(1,6,7,8~tetrahydro~2H-indeno[5,4-b]furan—8-
yl)ethyl]propionamide, as compared to that by oral
administration, a disintegration time of not more than 30 sec,
and te hardness of not less than 1.0 N/nm3.
A preparation for oral-mucosal absorption comprising (S)—
N—[Z—(l,6,7,8-tetrahydro—2H-indeno[5,4~b]furan-8—
yl)ethyl]propionamide, sugar or sugar l, and a
disintegrant; which shows not less than about 10—fold improved
bioavailability of (S)—N-[2-(l,6,7,8-tetrahydro-2H-indeno[5,4—
b]furan—B-yl)ethlepropionamide, as compared to that by oral
administration, and a disintegration time of not more than 30
sec.
A preparation for oral-mucosal tion comprising (S)—
N—[2-(1,6,7,8~tetrahydro—2H~indeno[5,4~b]furan~8—
yl)ethyl]propionamide, sugar or sugar alcohol, and a
egrant; which shows not less than about 10—fold improved
bioavailability of (S)~N-[2~(1,6,7,8—tetrahydro~2H—indeno[5,4—
b]furan—B—yl)ethyl]propionamide, as compared to that by oral
administration, a disintegration time of not more than 30 sec,
and te hardness of not less than 1.0 N/HmF.
[17] The preparation of any of the above—mentioned [9] ~ [16],
which is a tablet.
The preparation of the above-mentioned [9] or [12], which
is in the form of a film, troche, solution, suspension,
freeze—dried preparation, chewing gum or spray.
[0009]
PCT/320121051279
A method for the prophylaxis and/or treatment of a
bipolar disorder comprising administering (S)—N—[2—(l,6,7,8~
tetrahydro—ZH—indenoES,4—b]furan-S—yl)ethyl]propionamide oral—
mucosally to a human.
[20] The method of the mentioned [19], wherein the oral—
mucosal administration is sublingual stration or buccal
administration (more preferably sublingual administration).
The method of the above~mentioned [19], wherein (S)—N—[2—
(l,6,7,8-tetrahydro—2H-indeno[5,4—b]furan—B—
yl)ethyl]propionamide is administered in 0.05 — 1.0 mg per day.
The method of the above~mentioned [19], wherein the
bipolar disorder is bipolar disorder I.
The method of the above—mentioned [19], wherein the
prophylaxis and/or treatment of a bipolar disorder is a
treatment of a sion symptom associated with the bipolar
disorder or maintenance of a ion phase of the bipolar
disorder.
A drug for the prophylaxis and/or treatment of a bipolar
disorder, which comprises, as an active ingredient, (S)—N—[2~
(l,6,7,8—tetrahydro—2H—indeno[5,4—b]furan-8—
yl)ethyl]propionamide to be oral—mucosally administered to a
human.
The drug of the above~mentioned [24], wherein the oral—
l administration is gual administration or buccal
administration (more preferably sublingual administration).
The drug of the mentioned [24], wherein (S)—N—[2—
(l,6,7,8~tetrahydro~2H~indeno[5,4—b]furan—B—
yl)ethyl]propionamide is administered in 0.05 — 1.0 mg per day.
The drug of the above-mentioned [24], wherein the bipolar
disorder is bipolar disorder I.
The method of the above-mentioned [24], wherein the
prophylaxis and/or treatment of a r disorder is a
treatment of a depression symptom associated with the bipolar
disorder or maintenance of a remission phase of the bipolar
disorder.
(S)—N—[2—(1,6,7,8~tetrahydro~2H~indeno[5,4eb]furan—B—
yl)ethyl]propionamide for the prophylaxis and/or ent of
a bipolar disorder by oral—mucosal stration to a human.
The (S)—N—[2—(1,6,7,8—tetrahydro—2H—indeno[5,4-b]furan—8—
yl]propionamide of the above—mentioned [29], wherein the
oral—mucosal administration is sublingual stration or
buccal administration (more preferably sublingual
administration).
The [2—(1,6,7,8~tetrahydro~2H~indeno[5,4—b]furan-S—
yl)ethyl]propionamide of the above—mentioned [29], which is
administered in 0.05 — 1.0 mg per day.
The (S)—N—[2—(1,6,7,8—tetrahydro—2H-indeno[5,4—b]furan~8—
yl)ethyl]propionamide of the above—mentioned [29], wherein the
bipolar disorder is bipolar disorder I.
[33] The (S)—N—[2—(1,6,7,8-tetrahydro-2H-indeno[5,4—b]furan-8—
yl)ethyl]propionamide of the above—mentioned [29], wherein the
prophylaxis and/or treatment of the bipolar disorder is a
treatment of a depression symptom associated with the bipolar
disorder or maintenance of a remission phase of the bipolar
disorder.
The method of the above—mentioned [19] — [23], wherein
(S)—N—[2—(1,6,7,8—tetrahydro—2H—indeno[5,4—b]furan—B—
yl)ethyl]propionamide is administered as the preparation of
the above~mentioned [5] — [7], or [9] — [18].
[35] The drug of the above—mentioned [24] — [28], wherein (S)—
1,6,7,8~tetrahydr0*2H—indeno[5,4—b]furan—8—
yl)ethyl]propionamide is administered as the preparation of
the above—mentioned [5] ~ [7], or [9] — [18].
The (S)—N—[2—(1,6,7,8-tetrahydro—2H—indeno[5,4—b]furan—B—
yl)ethyl]propionamide of the above—mentioned [29] — [33],
which is stered as the preparation of the above—
mentioned [5] — [7], or [9] — [18].
Effect of the Invention
According to the present invention, a rapidly
WO 99260 PCT/JPZOIZ/051279
disintegrating preparation superior in the disintegration
property, a preparation with improved medicament
bioavailability and production methods thereof and the like
can be provided.
The rapidly disintegrating preparations [1] to [7] of the
present invention contain a medicament in granules, and a
disintegrant as an extragranule component. Even when a
medicament (e.g., compound A etc.) with poor compatibility
with the disintegrant is to be used, therefore, an nce
of the disintegrant on the medicament can be reduced, thus
improving the stability of the medicament.
The rapidly disintegrating preparation of the present
invention can improve disintegration property by enclosing a
component that prevents disintegration (e.g., masking agent,
binder etc.) in granules. In on, it can achieve high
disintegration ty by ensuring the invasion route of
water into the preparation by coating the component that
prevents disintegration with sugar or sugar alcohol. Moreover,
in the rapidly disintegrating preparation of the present
invention, a ment is coated with sugar or sugar alcohol.
Therefore, the dissolution property of the medicament from the
preparation can be improved even when the medicament has high
surface hydrophobicity, by altering the e to be
hydrophilic.
The rapidly egrating preparation of the present
invention can e both the good disintegration property
and the good ation hardness.
Among the rapidly egrating ations [1] to [7]
of the present invention, the rapidly disintegrating
preparations [5} to [7] for oral~mucosal absorption of the
present invention are expected to provide an immediate effect
by abSorption of the medicament from the oral mucosa.
The rapidly disintegrating ation for oral—mucosal
absorption of the present invention can improve
bioavailability by increasing the blood concentration of a
medicament (e.g., compound A etc.) susceptible to a first pass
effect by oral administration. In addition, the rapidly
disintegrating preparation for oral-mucosal tion of the
present invention can suppress inconsistent absorption of such
medicaments, and further, inconsistent iveness as
medicaments. Moreover, the rapidly disintegrating ation
for oral—mucosal absorption of the present invention can
afford a low dose medicament and a compact preparation based
on the improved medicament bioavailability.
According to the production method of the present
invention, the rapidly disintegrating preparations [1] to [7]
of the present invention having the above—mentioned effects
can be produced.
iption of Embodiments]
[0011]
The rapidly disintegrating ation of the_present
invention is explained in detail in the following.
The rapidly disintegrating preparation of the present
invention contains granules sing a medicament coated
with a coating layer ning sugar or sugar alcohol, and a
disintegrant.
While the medicament to be used in the present invention
is not particularly limited, for example, antipyretic
analgesic antiphlogistic drugs, antipsychotic drugs,
antianxiety drugs, antidepressant drugs, ve—hypnotic
drugs, gastrointestinal drugs, antacid drugs, ssive
expectorant drugs, antihypertensive agents, drugs for es,
drugs for osteoporosis, skeleton muscle relaxants, anti-cancer
agents and the like can be recited.
In the rapidly disintegrating preparation of the present
invention, the content of the medicament is generally 0.03 —
50 wt%, preferably 0.03 ~ 20 wt%, more preferably 0.03 - 3 wt%,
relative to the total weight of the ation.
The rapidly disintegrating preparation of the present
W0 2012f099260
invention contains a disintegrant as an extragranule component,
and therefore, an influence of the disintegrant on the
medicament can be reduced even when a medicament having poor
compatibility with the disintegrant is used, and the
medicament stability can be improved. Thus, the present
invention is particularly effective when a medicament having
poor compatibility with the disintegrant (e.g. compound A,
etc) is used as a medicament.
Compound A is a known therapeutic agent for sleep
ers, which is disclosed in US Patent No. 6034239 and the
like, and can be produced by a known method such as the method
described in this document and the like.
In the rapidly disintegrating preparation of the present
invention, an ent is contained in granules comprising a
medicament coated with a coating layer containing sugar or
sugar alcohol.
es of the ent include starches such as corn
starch and the like; sugar or sugar ls such as lactose,
fructose, glucose, mannitol (e.g., D—mannitol), sorbitol (e.g.,
D-sorbitol), erythritol (e.g., D—erythritol), sucrose and the'
like: anhydrous calcium phosphate, microcrystalline ose,
micromicrocrystalline cellulose, powdered glycyrrhiza, sodium
hydrogen ate, calcium phosphate, m sulfate,
calcium carbonate, precipitated calcium carbonate, calcium
silicate and the like, and corn starch, D—mannitol and
microcrystalline cellulose are preferable.
The content of the excipient is generally 13 - 94 wt%,
preferably 54 — 94 wt%, more preferably 81 — 93 wt%, relative
to the total weight of the preparation.
The y disintegrating preparation of the present
invention may further contain an additive, where necessary, in
the granules comprising a medicament.
Examples of the additive optionally contained in the
PCT/JPZOlZ/051279
granules comprising a medicament include , masking agent,
solubilizer and the like, which may be used in combination
where necessary.
Examples of the binder include starches such as potato
starch, wheat , rice starch, partly pregelatinized
starch, pregelatinized starch, porous starch and the like,
hydroxypropylcellulose, hydroxypropylmethylcellulose,
polyvinylpyrrolidone, gelatin, starch, gum arabic powder,
tragacanth, carmellose, sodium te, pullulan, ol
and the like, and partly pregelatinized starch,
hydroxypropylcellulose and pregelatinized starch are
preferable.
The content of the binder is generally 0.5 — 20 wt%,
preferably 0.5 — 15 wt%, more preferably 1 — 10 wt%, relative
to the total weight of the preparation.
Examples of the masking agent include s flavoring
agents (thaumatin, sucralose, saccharin, aspartame, l,
citric acid, L—sodium glutamate etc.), various receptor
antagonists (BENECOAT, sodium de etc.), various cation
channel antagonists (L—arginine etc.), various clathration
agents (g—cyclodextrin, B—cyclodextrin etc.), various flavors
(strawberry flavor, mint flavor, orange flavor, vanillin etc.)
and the like. Two or more thereof may be used in ation
where necessary.
The content of the masking agent is generally 0.01 — 10
wt%, ably 0.01 — 5 wt%, more preferably 0.01 — 1 wt%,
ve to the total weight of the preparation.
Examples of the solubilizer include various aqueous
solvents (polyethylene glycol, propylene glycol, glycerol
etc.), various clathration agents lodextrin, B—
cyclodextrin etc.), various surfactants (sodium lauryl sulfate,
polysorbate 80, polyoxyethylene(l60)polyoxypropylene(30)glycol
etc.) and the like. Two or more thereof may be used in
combination where necessary.
The content of the solubilizer is generally not more than
wt%, preferably not more than 15 wt%, more preferably not
more than 10 wt%, relative to the total weight of the
ation.
In the rapidly disintegrating preparation of the present
invention, egration property can be improved by
including a component that prevents disintegration (e.g.,
masking agent, binder, lizer etc.) in granules. In
addition, as mentioned below, the preparation can achieve high
disintegration property by ensuring the invasion route of
water into the preparation by coating the component that
prevents disintegration with sugar or sugar alcohol.
The rapidly disintegrating preparation of the present
invention contains sugar or sugar alcohol in a coating layer
formed on the granules comprising a medicament.
Examples of the sugar or sugar alcohol e lactose,
fructose, glucose, mannitol (e.g., itol), sorbitol (e.g.,
D—sorbitol), erythritol (e.g., D—erythritol), sucrose and the
like, and D-mannitol is preferable.
The preparation can achieve high disintegration property
by ensuring the invasion route of water into the preparation
by coating the granules comprising a medicament with sugar or
sugar alcohol. In addition, the dissolution property of the
medicament from the preparation can be improved.
The content of the sugar contained in the coating layer
is generally 5 — 20 wt%, preferably 5 — 15 wt%, more
preferably 5 - 10 wt%, relative to the total weight of the
preparation.
The content of the sugar alcohol contained in the coating
layer is generally 5 — 20 wt%, preferably 5 — 15 wt%, more
preferably 5 — 10 wt%, relative to the total weight of the
preparation.
The content of the sugar and sugar alcohol contained in
the coating layer is generally 5 - 20 wt%, ably 5 - 15
wt%, more ably 5 — 10 wt%, relative to the total weight
2012/051279
of the preparation.
The rapidly disintegrating ation of the present
invention may further contain an additive in the coating layer
as necessary.
Examples of the ve optionally contained in the
coating layer include excipient, disintegrant and the like,
which may be used in combination as necessary.
Examples of the excipient include starches such as corn
starch and the like; anhydrous calcium phosphate,
microcrystalline cellulose, micromicrocrystalline cellulose,
powdered glycyrrhiza, sodium en carbonate, calcium
phosphate, calcium e, calcium carbonate, precipitated
calcium carbonate, calcium silicate and the like, and corn
starch and microcrystalline cellulose are preferable.
Examples of the disintegrant include amino acid, starch,
corn starch, carmellose, carmellose sodium, carmellose m,
croscarmellose sodium, crospovidone, low—substituted
hydroxypropylcellulose, ypropyl starch, sodium
carboxymethyl starch and the like, and crospovidone and
carmellose are preferable.
In the rapidly disintegrating ation of the present
invention, the average particle size of the “granules
comprising a medicament coated with a coating layer ning
sugar or sugar alcohol” is generally 50 um — 500 pm,
ably 50 um — 355 pm, more preferably 50 um - 150 pm.
In the present specification, the average particle size
is a value measured by a laser diffraction particle size
analyzer, SYMPATEC: HELOS&RODOS and the like.
In the rapidly disintegrating preparation of the present
invention, examples of the disintegrant contained as an
extragranule component include amino acid, starch, corn ,
carmellose, carmellose sodium, carmellose calcium,
croscarmellose sodium, crospovidone, low-substituted
hydroxypropylcellulose, hydroxypropyl starch, sodium
carboxymethyl starch and the like, and crospovidone and
carmellose are preferable.
The content of the disintegrant is generally 0.5 — 15 wt%,
preferably 1 — 10 wt%, more preferably 2 — 5 wt%, relative to
the total weight of the preparation.
In the rapidly disintegrating ation of the present
invention, examples of the ant optionally contained as
an extragranule component e magnesium stearate, stearic
acid, calcium stearate, talc (purified talc), sucrose esters
of fatty acid, sodium stearyl te and the like, and
sodium stearyl te is preferable.
The content of the lubricant is generally 0.5 — 2 wt%,
preferably 0.5 — 1.5 wt%, more preferably 0.5 - 1 wt%,
relative to the total weight of the preparation.
The rapidly disintegrating preparation of the present
invention may further contain an additive as an extragranule
component where necessary.
es of the additive include masking agent,
solubilizer and the like, explained above, which may be used
in combination where necessary.
[0021]
The rapidly disintegrating preparation of the present
ion is not only useful as a so—called “orally
disintegratable preparation” aiming at oral administration of
a medicament, but also preferable as a preparation for oral-
mucosal tion (particularly, sublingual preparation,
buccal preparation).
The rapidly disintegrating preparation for oral-mucosal
absorption of the present invention can be expected to show
immediate effect by absorption from the oral mucosa.
The rapidly disintegrating preparation for oral—mucosal
absorption of the present invention is particularly ive
when a medicament (e.g., nd A etc.) tible to a
first pass effect by oral administration is used. The rapidly
disintegrating preparation for oral—mucosal absorption of the
present invention can improve bioavailability by increasing
the blood concentration of such ment. In addition, the
rapidly disintegrating preparation for oral—mucosal absorption
of the present invention can suppress inconsistent absorption
of such medicaments, and further, inconsistent effectiveness
as medicaments. Moreover, the y disintegrating
preparation for oral—mucosal absorption of the present
invention can afford a low dose medicament and a compact
preparation based on the improved medicament bioavailability.
When compound A is particularly used as a medicament, the
rapidly disintegrating preparation for oral-mucosal absorption
of the present invention shows an effect in that the ratio of
the medicament in an unchanged form and a metabolite of the
medicament after transfer into blood is higher than that by
oral administration. In addition, the rapidly egrating
preparation for oral—mucosal tion of the present
invention shows not less than about d improved
bioavailability of compound A, as compared to that by oral
administration.
While the dosage form of the rapidly disintegrating
ation of the present invention is not particularly
limited, it is preferably a tablet.
When the rapidly egrating ation of the
present invention is a tablet, the weight of the preparation
is preferably about 20 - 200 mg.
When the rapidly disintegrating preparation of the
present invention is a tablet, the absolute hardness is
generally not less than 1.0 N/Hm3, preferably not less than 1.5
W0 2012f099260 ZOIZ/051279
N/an, more preferably not less than 2.0 N/HmF. When the
rapidly disintegrating ation of the present invention is
a tablet, the absolute hardness is generally not more than 5.0
N/Hmfi.
[0025}
When the y disintegrating preparation of the
present invention is a tablet, the disintegration time is
generally not more than 30 sec, preferably not more than 15
sec, more preferably not more than 10 sec. When the rapidly
disintegrating preparation of the present invention is a
tablet, the disintegration time is generally not less than 1
sec.
[0026}
In the rapidly disintegrating preparation of the present
invention, the egration ty can be improved by
including, in granules, a component that prevents
disintegration, as described above. In on, it can
achieve high disintegration property by ensuring the invasion
route of water into the preparation by coating the ent
that prevents disintegration with sugar or sugar alcohol.
Therefore, even when the rapidly disintegrating preparation of
the present invention is molded to have the above—mentioned
high absolute hardness, it shows good disintegration property.
Thus, the rapidly disintegrating preparation of the present
invention can achieve both the good disintegration property
and the good preparation hardness.
The rapidly disintegrating preparation of the present
invention preferably shows a disintegration time of not more
than 30 sec, and absolute hardness of not less than 1.0 N/mma
[0027]
The rapidly disintegrating ation of the present
invention can be produced by a method conventionally used in
the pharmaceutical—technical field. For example, the
preparation can be produced by the following production method
of the rapidly egrating preparation of the present
invention.
The production method of the rapidly disintegrating
preparation of the present invention includes
step (1): producing granules comprising a medicament,
step (2): forming a coating layer containing sugar or sugar
alcohol on the obtained granules, and
step (3): mixing the coated granules with a disintegrant and
molding the mixture.
In steps (1) — (3), an ve may be further added as
necessary. As the kind and amount of the “medicament”, “sugar”,
“sugar alcohol”, “disintegrant” and “additive” to be used in
steps (1) — (3), those exemplified for the mentioned
rapidly disintegrating preparation can be mentioned. As the
particle size of the coated granules obtained in step (2), the
range ified as the particle size of the “granules
comprising a medicament coated with a coating layer containing
sugar or sugar alcohol” of the above—mentioned rapidly
disintegrating preparation can be mentioned
The production of the granule in step (1) and formation
of the g layer in step (2) can also be d out
simultaneously.
For example, the preparation can be ically ed
as follows.
Sugar or sugar alcohol (e.g., D-mannitol etc.) is
dissolved in a suitable solvent (e.g., water etc.) to give a
coating solution.
A medicament (e.g., compound A etc.) and any additive
(e.g., excipient such as D—mannitol, microcrystalline
cellulose and the like, binder such as partly atinized
starch and the like etc.) are mixed to give a mixture. The
obtained mixture is granulated while spraying the coating
solution thereon, and dried to give a granulated powder
(coated es). The obtained granulated powder (coated
WO 99260 PCT/JPZOlZ/051279'
granules) may be sieved as necessary.
The obtained coated granules, a disintegrant (e.g.,
crospovidone etc.) and any additive (e.g., ant such as
sodium stearyl fumarate etc., and the like) are mixed to give
a mixed powder. The obtained mixed powder is compression—
molded to give a tablet.
Here, the mixing (including granulation, drying, g
and the like) is carried out by using a preparation machine,
for example, V—type mixer, tumbler mixer (TM—30, ;SHOWA
KAGAKU KIKAI CO., LTD.: TMZOvo—O; Suehiro Kakoki CO., Ltd.),
high speed mixer granulator —lO; POWREX ATION),
universal kneader (HATA IRON WORKS CO., LTD.), fluid bed dryer
granulator (LAB—l, FD—3S, FD—BSN, FD—SS; POWREX CORPORATION),
box type vacuum dryer (Kusuki Kikai Seisakusho), power mill
grinding machine (P—3, SHOWA KAGAKU KIKAI CO., LTD.),
centrifugation rolling granulator (CF—mini, CF-260, CF—360;
Freund Corporation), dry type granulator, spray-drying
granulator, rolling granulator (MP—10; POWREX CORPORATION) and
the like.
Coating is carried out by using, for example, a
preparation machine, for example, centrifugation rolling
granulator (CF—mini, , CF-360; Freund Corporation),
rolling granulator (MP—10; POWREX CORPORATION), general
fluidized bed coater, wurster—type coater and the like.
Compression molding is carried out by using, for example,
single punch tableting machine (Kikusui Seisakusho Ltd.),
rotary tableting machine (AQUARIUS 36K, AQUARIUS 2L; Kikusui
Seisakusho Ltd.), AUTOGRAPH (AG—50008, SHIMADZU Corporation)
and the like, and by ng generally at a pressure of l —
3O kN.
In addition to the application of the above—mentioned
“rapidly disintegrating preparation of the present invention"
to nd A, the t inventors have ively studied
WO 99260 -
a preparation superior in the absorption of compound A from
the oral mucosa and having improved bioavailability of
compound A, and completed the following ion.
That is, the present invention also relates to a
preparation for oral—mucosal absorption containing compound A
as a medicament; which shows a higher ratio of the medicament
in an unchanged form and a metabolite of the medicament after
transfer into blood than that by oral administration
(preparations [9] to [11], [17] and [18]) (hereinafter
sometimes to be abbreviated as preparation (A) of the present
invention).
When the dosage form of preparation (A) is a , the
disintegration time is ably not more than 30 sec. When
the dosage form in preparation (A) is a , more
preferably, the disintegration time is not more than 30 sec,
and the absolute hardness is not less than 1.0 N/Hmf.
The aforementioned preparations [5] to [7] are also
encompassed in the “preparation (A)”.
[0033]
The present invention also relates to a preparation for
oral—mucosal absorption, which contains compound A, and shows
not less than about 10—fold improved bioavailability of
compound A, as compared to that by oral administration
(preparations [12] to [18]) (hereinafter sometimes to be
abbreviated as preparation (B) of the present invention). Here,
“about” means 5% error range. The bioavailability is generally
improved within the range of not more than about d, more
specifically not more than about 20—fold.
When the dosage form of ation (B) is a tablet,
preferably, the disintegration time is not more than 30 sec.
When the dosage form in preparation (B) is a tablet, more
preferably, the disintegration time is not more than 30 sec,
and the absolute ss is not less than 1.0 N/Hmfi.
The aforementioned preparations [5] to [7] are also
PCT/JPZOIZ/051279
encompassed in the “preparation (B)”.
Here, whether or not “bioavailability of compound A is
improved not less than about 10-fold as compared to oral
administration” is evaluated as follows.
Each ation is administered intravenously, orally or
oral—mucosally, the plasma concentration after lapse of each
time period is measured, and the area under the plasma
concentration time curve (AUC) is calculated according to the
oidal rule. In addition, bioavailability (BA) is
calculated according to the following formula.
BA (%)=(oral or oral—mucosal administration
AUG/intravenous administration AUC)XlOO.
The ratio of the calculated BA by oral—mucosal
administration relative to the calculated BA by oral
administration (that is, BA by oral—mucosal administration/BA
by oral administration) is calculated.
In this case, when the “ratio of the BA by oral—mucosal
administration relative to the BA by oral stration” is
not less than 10, the preparation is evaluated to show “not
less than about 10—fold ed bioavailability of compound A
as compared to that by oral administration”.
As for the specific preparations to be
subjected to a
test and test methods, the below—mentioned mental
e 3 can be referred to. However, when a substantially
similar evaluation is possible, the method is not d to
that of Experimental Example 3.
The present invention also relates to a preparation for
oral-mucosal absorption, which contains compound A and shows a
higher ratio of a medicament in an unchanged form and a
metabolite of the medicament after er into blood than
that by oral administration (preparations [9] to [11])
(hereinafter sometimes to be abbreviated as preparation (C) of
the present invention).
The “greater than the ratio” specifically means not less
than about 5-fold, preferably not less than about 10—fold. It
is generally not more than about 30—fold, more specifically
not more than about 20-fold” Here, ” means 5% error
range.
When the dosage form of preparation (C) is a tablet,
preferably, the disintegration time is not more than 30 sec.
When the dosage form of preparation (C) is a tablet, more
preferably, disintegration time is not more than 30 sec, and
the absolute ss is not less than 1.0 N/ng.
The aforementioned preparations [5] to [7] are also
encompassed in the “preparation (C)”.
Here, whether or not the “ratio of the medicament in an
unchanged form and a metabolite of the medicament after
transfer into blood is higher than that by oral
administration” is evaluated as follows.
Each ation is administered orally or oral-mucosally,
the plasma concentration of both the unchanged form and
metabolite after lapse of each time period is measured, and
the area under the plasma concentration time curve (AUC) of
the both is calculated according to the oidal rule. The
ratio of the unchanged form and metabolite (i.e., AUC of
unchanged form/AUG of metabolite) in each preparation is
calculated.
In this case, when the ratio by oral-mucosal
administration is higher than that by oral administration, it
is evaluated “the ratio of a medicament in an unchanged form
and a metabolite of the medicament after transfer into blood
is higher than that by oral stration”.
As for the specific preparations to be subjected to a
test and test methods, the below—mentioned Experimental
Example 4 can be referred to. However, when a ntially
similar evaluation is possible, the method is not limited to
that of Experimental Example 4.
While the dosage forms of preparation (A), preparation
(B) and preparation (C) are not particularly limited as long
PCT/JPZOIZ/051279
as they can be administered from the oral mucosa. For example,
tablet (e.g., sublingual tablet, buccal tablet), film, ,
solution, suspension, freeze—dried preparation, chewing gum,
spray and the like can be mentioned. Among these, tablet is
able.
As the kind and amount of “compound A”, “masking agent”,
”, “sugar alcohol” and “disintegrant” to be used for
preparation (A), preparation (B) or preparation (C), those
ified for the above—mentioned rapidly disintegrating
preparation can be mentioned.
In the present specification, the absolute ss is
hardness per unit area, and is defined according to the
following formula.
absolute hardness (N/Hm3)=hardness (N)/(thickness (mm)X
diameter (mm))
In the present invention, the tablet hardness can be
measured by a tablet hardness tester (TH—303MP, Toyama Sangyo
CO., LTD.).
[0036]
In the present specification, the disintegration time is
a value measured by a disintegration tester (CDT—101, Toyama
Sangyo CO., LTD.) for orally rapidly disintegrating tablet.
Preparations (A) — (C) can be produced, for example,
according to the production method explained for “the rapidly
disintegrating preparation of the present ion”.
ularly, when the dosage form of ations (A) - (C)
is tablet, such production method is preferable. It is also
possible to apply other techniques for orally disintegrating
preparations.
When the dosage form of preparations (A) — (C) is film,
the preparations can be produced according to a conventional
method as follows. For example, the preparation can be
produced by applying or spraying a coating solution (solution
W0 20121099260 PCT/JPZOlZ/051279
or suspension, solvent is, for e, purified water)
containing a medicament, a film carrier, other film rs
used as necessary and the like to the surface of a support
medium, and drying same (JP-B—3460538).
When the dosage form of preparations (A) - (C) is freeze—
dried preparation, the preparation can be ed according
to a tional method as follows. For example, the
preparation can be produced by mixing a medicament, a polymer,
sugars and the like, and dissolving and lyophilizing them
(Manufacturing Chemist, Feb. 36 (1990)).
When the dosage form of preparations (A) — (C) is g
gum, the preparation can be produced according to a
conventional method as s. For example, the preparation
can be produced by adding a medicament, additive such as
sweetener, flavor, colorant, softening agent, flavoring
substance and the like to a gum base containing a resin for a
gum base as a main component, wax, an fier and a filler,
uniformly kneading them in a kneader, and processing them into
a plate form, a block form and the like (JP-A136240).
When the dosage form of preparations (A) — (C) is troche,
the preparation can be produced according to a general
production method of tablets.
When the dosage form.of preparations (A) — (C) is
solution or suspension, the preparation can be produced
according to a l production method of liquids.
When the dosage form of preparations (A) — (C) is spray,
the preparation can be produced according to a general
production method of spray.
The preparation of the present invention can be safely
administered to a mammal (e.g., human, mouse, rat, rabbit, dog,
cat, bovine, horse, swine, monkey), ularly human.
The dose of the preparation of the present invention
varies depending on the subject of administration,
W0 099260 PCT/320121051279
administration route, disease and the like. For example, when
a preparation for oral~mucosal absorption containing compound
A as a medicament is administered to an adult, the dose of
compound A is about 0.0002 — about 0.02 mg/kg body weight,
preferably about 0.0002 — about 0.01 mg/kg body , more
preferably about 0.0002 — about 0.005 mg/kg body weight, most
preferably about 0.0002 — about 0.004 mg/kg body weight, which
can be administered in one to several portions a day.
It is known that melatonin secretion decreases to cause
disorders in the circadian rhythm in patients with bipolar
disorders. Compound A is a superior melatonin receptor agonist,
and considered to be effective for the prophylaxis or
treatment of diseases possibly influenced by melatonin. In
fact, compound A is ted to be effective for the
ent of bipolar disorders (particularly maintenance of
remission phase) in the clinical evaluation by oral
administration.
As mentioned above, the t invention provides a
preparation g superior absorption of compound A from the
oral mucosa and improved bioavailability thereof. Hence, a
more effective method for the prophylaxis and/or treatment of
bipolar ers, and a more effective drug for the
prophylaxis and/or treatment of r disorders are provided.
To be precise, by oral-mucosal administration of compound
A to patients affected with bipolar disorders, the bipolar
disorders can be prevented and/or treated. Specifically, such
prophylaxis and/or treatment can be performed by appropriately
administering the preparation of the present invention to
humans.
Here, the administration route of compound A is
preferably gual administration or buccal administration,
and sublingual administration is particularly able.
While the dose of compound A is as mentioned above, for
administration as a sublingual tablet or a buccal tablet, for
example, a tablet containing 0.05 — 1.5 mg (preferably, 0.05 ~
1.0 mg, more preferably, 0.1 ~ 1.0 mg, and most preferably,
0.1 mg, 0.4 mg and 0.8 mg) of nd A per tablet is
preferably stered to patients in one to three portions
(preferably once) per day.
As the target disease, it is particularly effective for
bipolar disorder I. Specifically, it is effective for the
“treatment of depression symptoms (particularly, acute
depression symptoms) associated with bipolar disorder” and
“maintenance of remission phase of bipolar disorder”.
For the “prophylaxis and/or treatment of bipolar
disorders by oral~mucosal administration of compound A”, other
medicaments for the prophylaxis and/or treatment of bipolar
disorders may be used in combination. Such other medicaments
for the prophylaxis and/or treatment of bipolar disorders to
be used in combination with “compound A” (hereinafter referred
to as “combination medicament”) may include mood stabilizer
(e.g. m, valproic acid, azepine, igine, etc)
and antipsychotics (e.g. pine, olanzapine, etc), and a
combination of one or more medicaments selected from them. In
addition thereto, one or more SSRI (selective serotonin
ke inhibitors) (e.g. fluvoxamine, paroxetine,
escitalopram, fluoxetine, citalopram, etc) may also be
administered in combination with “compound A” and the
aforementioned “combination medicament”.
The administration mode of the “combination medicament”
is not particularly restricted, and it is sufficient that
“compound A” and “combination ment” be combined in
administration. Examples of suCh'administration mode include
the following:
(1) administration of a single preparation obtained by
simultaneously processing “compound A” and “combination
medicament”,
(2) simultaneous administration of two kinds of preparations
of “compound A” and nation medicament”, which have been
PCTIJP2012/051279
separately produced, by the same administration route,
(3) administration of two kinds of preparations of “compound
A” and “combination ment”, which have been separately
produced, by the same stration route in a staggered
,
(4) simultaneous administration of two kinds of preparations
of und A” and “combination medicament”, which have been
separately produced, by different administration routes,
(5) administration of two kinds of preparations of und
A” and “combination medicament”, which have been separately
produced, by different administration routes in a staggered
manner (e.g., administration in the order of “compound A” and
“combination medicament”, or in the reverse order) and the
like.
The dosage of the “combination medicament” may be
determined according to the dose clinically used, and can be
appropriately selected depending on an administration subject,
administration route, seriousness of the disease, combination,
and the like.
The “combination medicament” can be administered in the
same dosage form as clinically used or in a different dosage
form suitable for this combination therapy.
When compound A is stered oral—mucosally to a
human subject, the blood kinetic of it is quite similar to
that of the endogenous nin, and therefore compound A can
regulate ian rhythm, which is thought to be disturbed in
bipolar patients, better than existing drugs and even
melatonin/other melatonin agonists. Thus, compound A is
expected to show superior effect on bipolar e to
existing drugs. In addition, this ian rhythm regulating
effect can also translate into better normalizing circadian
rhythm and/or sleep/awake cycle in bipolar patients.
Examples
The present invention is explained in more detail in
PCT/JPZOIZ/051279
the following by referring to Examples, which are not to be
construed as limitative. The preparation additives (e.g., D-
mannitol, microcrystalline cellulose, and the like) used in
the following Examples and Comparative Examples were the.
Japanese Pharmacopoeia 15th Edition or se Pharmaceutical
ents 2003 compatible products.
Example 1
(1) D—Mannitol (PEARLITOL 50C, te) (450.0 g) was
dissolved in purified water (2550 g) to give a coating
solution. Compound A (150.5 g), D-mannitol (3068 g),
microcrystalline cellulose (CEOLUS PH-lOl, Asahi Kasei
Corporation) (112.5 g), and partly atinized starch (PCS,
Asahi Kasei Corporation) (450.0 g) were uniformly mixed in a
fluid bed dryer granulator (FD—SS, POWREX ATION),
granulated while spraying the g solution (3000 g), and
dried to give a granulated powder. A part of the obtained
granulated powder was ground in a power mill grinding machine
(P-3, SHOWA KAGAKU KIKAI CO., LTD.) using a 1.5 mm¢ punching
screen to give a sieved powder.
(2) To the obtained sieved powder (1692 g) were added
crospovidone (Kollidon CL—F, BASF) (90 g) and sodium stearyl
fumarate (PRUV, JRS PHARMA) (18 g), and the mixture was mixed
in a tumbler mixer (TM—30, SHOWA KAGAKU KIKAI CO., LTD.) to
give a mixed powder.
(3) The mixed powder was tableted by a rotary tableting
machine (AQUA O8242L2JI, Kikusui Seisakusho Ltd.) using a 4 mm¢
punch (tableting re: 4 kN, weight per tablet: 30 mg) to
give "'
a tablet.
[0043]
Composition of preparation (30 mg)
compound A 1.0 mg
D-mannitol (in granules) 20.45 mg
D—mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
PCT/JPZOIZ/051279
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
total 30 mg
[0044]
ative Example 1
hylene glycol 400 (PEG400) (Wako Pure Chemical
Industries, Ltd.) (15 g) was dissolved in purified water (35
g) to give PEG400 solution. Compound A (12.5 mg) was added to
PEG400 solution (50 ml), and the mixture was stirred and
insonated, and filtered using a hydrophilic filter (0.45 pm).
The obtained compound A solution was divided into small
portions (1 ml each).
Composition of preparation (1 ml)
compound A 0.25 mg
PEG400 300.0 mg
purified water 700.0 mg
total 5 mg
[0046]
Comparative Example 2
(l) Hydroxypropylcellulose (HPC—L, NIPPON SODA CO., LTD.) (40
g) was dissolved in ed water (627 g) to give a binding
solution. Compound A (2.5 g), lactose (DMV ATIONAL)
(1053.5 9), and corn starch (Japan Corn Starch Co., Ltd.) (160
g) were uniformly mixed in a fluid bed dryer ator (MP—01,
POWREX CORPORATION), granulated while spraying the binding
solution (667 g), and dried to give a granulated powder. The
obtained granules were sieved through a 16 mesh (aperture 1.0
mm) sieve to give a sieved powder.
(2) Corn starch (17 g) and magnesium te (5 g) were added
to the obtained sieved powder (628 g) and mixed in a bag to
give a mixed powder.
(3) The mixed powder was tableted by a rotary tableting
machine (compact tableting machine, Kikusui Seisakusho Ltd.)
W0 20121099260
, PCT/JPZOlZ/051279
by using a 4 mm¢ punch (tableting pressure: 7 kN, weight per
tablet: 130 mg) to give a tablet (core tablet).
(4) Hydroxypropylmethylcellulose (TC—5R) (22.44 g) and
done (4.5 g) were dissolved in purified water (198 g)
and dispersed therein to give dispersion I. Titanium oxide (25
g) and yellow ferric oxide (0.5 g) were dispersed in purified
water (450 g) to give dispersion II. Dispersion II was added
to dispersion I, and the mixture was stirred to give a coating
solution. The coating solution was d on the core tablet
obtained in (3) until the weight of the core tablet increased
by 5 mg per tablet by using a coater (High Coater HC~LABO,
Freund Corporation) to give a film—coated tablet having the
following composition.
ition of preparation (135 mg)
compound A 0.25 mg
e 105.35 mg
corn starch 19.4 mg
hydroxypropylcellulose 4.0 mg
magnesium stearate 1.0 mg
hydroxypropylmethylcellulose 3.74 mg
Copovidone 0.75 mg
titanium oxide 0.5 mg
yellow ferric oxide 0.01 mg
total 135 mg
Example 2
(1) D—Mannitol (PEARITOL 50C, Roguette) (120 g) was dissolved
in purified water (680 g) to give a coating solution. Compound
A (10 g), D—mannitol (848 g), microcrystalline cellulose
(CEOLUS PH—lOl, Asahi Kasei ation) (30 g), and partly
pregelatinized starch (PCS, Asahi Kasei Corporation) (120 g)
were uniformly mixed in a fluid bed dryer granulator (MP—01,
POWREX CORPORATION), granulated while spraying a g
solution (800 g), and dried to give a ated powder. The
012/051279
obtained es were sieved through a 16 mesh ure 1.0
mm) sieve to give a sieved powder.
(2) The obtained sieved powder (28.2 g), crospovidone
(Kollidon CL—F, BASF) (1.5 g) and sodium stearyl fumarate (0.3
g) were mixed in a glass bottle. The obtained mixture was
tableted (tableting pressure: 3 KN/punch, tablet weight per
tablet: 30 mg) by an AUTOGRAPH (AG-5000B, SHIMADZU
Corporation) using a 4 mm¢ punch to give a core tablet with the
following composition.
[0049]
Composition of preparation (30 mg)
compound A 0.25 mg
itol (in granules) 21.2 mg
D—mannitol (in g layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly pregelatinized starch 3 0 mg
vidone 1.5 mg
sodium stearyl fumarate 0 3 mg
total 30 mg
[0050]
Comparative Example 3
PEG4OO (Wako Pure Chemical Industries, Ltd.) (60 g) was
dissolved in purified water (110 g) to give PEG400 solution.
Compound A (100.0 mg) was added to the PEG4OO solution (100
m1), and the mixture was stirred and insonated, and filtered
using a hydrophilic filter (0.45 pm). The obtained compound A
solution was divided into small portions (1 ml each).
Composition of preparation (1 ml)
compound A 1.0 mg
PEG4OO 352.9 mg
purified water 647.1 mg
total 1001 mg
Comparative Example 4
PCT/JPZOIZ/051279
(1) Hydroxypropylcellulose (HPC~L, NIPPON SODA CO., LTD.) (660
g) was dissolved in purified water (10230 g) to give a binding
solution. Compound A (165.3 g), lactose (DMV INTERNATIONAL)
(17260 g), and corn starch (Japan Corn Starch Co., Ltd.) (2640
g) were uniformly mixed in a fluid bed dryer granulator ,
POWREX ATION), granulated while spraying a binding
solution (10890 g), and dried to give a granulated powder.
This granulation step was performed twice. A part of the
ed ated powder was ground by a power mill grinding
machine (P—3, SHOWA KAGAKU KIKAI CO., LTD.) using a 1.5 mm¢
punching screen to give a sieved powder.
(2) Corn starch (1013 g) and magnesium stearate (298 g) were
added to the obtained sieved powder (37430 g), and the mixture
was mixed in a tumbler mixer O-O, Suehiro Kakoki Co.,
Ltd.) to give a mixed powder.
(3) The mixed powder was tableted by a rotary ing
machine (AQUARIUS 36K, Kikusui Seisakusho Ltd.) by using a 7
mm¢ punch (tableting pressure: 7 kN, weight per tablet: 130 mg)
to give a tablet (core tablet).
(4) Hydroxypropylmethylcellulose (TC~5R, Shin-Etsu Chemical
Co., Ltd.) (1548 g) and Copovidone (310.5 g) were dissolved in
purified water (16150 g) and dispersed therein to give
dispersion I. Titanium oxide (207 g) and yellow ferric oxide
(4.14 g) were dispersed in purified water (1822 g) to give
dispersion II. Dispersion II was added to sion I, and
the mixture was stirred to give a coating solution. Using a
coater (High Coater HCF~1OON, Freund Corporation), the coating
solution was sprayed on the core tablet obtained in (3) until
the weight of the core tablet increased by 5 mg per tablet to
give a film-coated tablet having the following composition.
Composition of preparation (135 mg)
compound A 1.0 mg
lactose 104.6 mg
corn starch 19.4 mg
WO 99260 PCT/JPZOlZ/051279
hydroxypropylcellulose 4.0 mg
magnesium stearate 1.0 mg
hydroxypropylmethylcellulose 3.74 mg
Copovidone 0.75 mg
titanium oxide 0.5 mg
yellow ferric oxide 0.01 mg
total 135 mg
Example 3
(1) D~mannitol (PEARLITOL 50C, te) (120 g) was dissolved
in purified water (680 g) to give a coating solution. Compound
A (40 g), D~mannitol (818 g), microcrystalline cellulose
(CEOLUS PH—lOl, Asahi Kasei Corporation) (30 g), and partly
pregelatinized starch (PCS, Asahi Kasei Corporation) (120 g)
were uniformly mixed in a fluid bed dryer ator (MP—01,
POWREX CORPORATION), ated while spraying the g
solution (800 g), and dried to give a granulated powder. The
obtained granules were sieved through a 16 mesh (aperture 1.0
mm) sieve to give a sieved powder.
(2) The obtained sieved powder (28.2 g), crospovidone
(Kollidon CL—F, BASF) (1.5 g) and sodium stearyl fumarate (0.3
g) were mixed in a glass bottle. The obtained mixture was
tableted (tableting pressure: 3 KN/punch, tablet weight per
tablet: 30 mg) by an APH (AG-5000B, SHIMADZU
Corporation) by using a 4 mm¢ punch to give a core tablet with
the following composition.
Composition of preparation (30 mg)
compound A 1.0 mg
D—mannitol (in es) 20.45 mg
D—mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
2012/051279
total 30 mg
Compound A (5 g) and CMEC (20 g) were dissolved in
acetone:ethanol=3:2 mixed solution (500 ml), and spray—dried
by a spray dryer (Pulvis Mini Spray, YAMATO SCIENTIFIC CO.,
LTD.). The obtained solid dispersion powder was dried in vacuo
at 40°C for 16 hr. To the solid dispersion powder (0.5 g) was
added D—mannitol (PEARLITOL lOOSD, Roquette) (11.5 g) and
mixed in a bottle. The obtained mixed powder was divided into
small portions (120 mg each).
Composition of preparation (120 mg)
compound A 1.0 mg
CMEC 4.0 mg
D~mannitol 115.0 mg
total 120 mg
Example 5
Hydroxypropyl—B—cyclodextrin (hereinafter sometimes
referred to as HP—B—CyD) (KLEPTOSE HPB, Roquette) (75 g) was
dissolved in purified water (422.5 g). Compound A (2.5 g) was
dissolved in the obtained HP~B—CyD aqueous solution to give a
g on. D—Mannitol ITOL 50C, Roquette) (200 g)
and microcrystalline cellulose (CEOLUS PH—lOl, Asahi Kasei
Corporation) (7.5 g) were uniformly mixed in a fluid bed dryer
granulator (MP—01, POWREX CORPORATION), granulated while
spraying the g solution (500 g), and dried to give a
granulated powder. The obtained granules were sieved through a
16 mesh (aperture 1.0 mm) sieve to give a sieved powder. The
ed sieved powder was divided into small portions (114 mg
each).
Composition of preparation (114 mg)
compound A 1.0 mg
ZOIZI'051279
HP-B-CyD 30.0 mg
D-mannitol 80.0 mg
microcrystalline cellulose 3.0 mg
total 114 mg
Example 6
(l) D-Mannitol (PEARLITOL 50C, Roquette) (450 g) was dissolved
in purified water (2550 g) to give a coating solution.
Compound A (37.6 g), D—mannitol (3180 g), microcrystalline
cellulose S PH—lOl, Asahi Kasei Corporation) (112.5 g),
and partly pregelatinized starch (PCS, Asahi Kasei
Corporation) (450 g) were uniformly mixed in a fluid bed dryer
granulator (FD—SS, POWREX CORPORATION), granulated while
spraying the coating solution (3000 g), and dried to give a
granulated powder. A part of the obtained granulated powder
was ground by a power mill grinding e (P—3, SHOWA KAGAKU
KIKAI CO., LTD.) using a 1.5 mm¢ punching screen to give a
sieved powder. ‘
(2) Crospovidone don CL-F, BASF) (90 g) and sodium
stearyl fumarate (18 g) were added to the obtained sieved
powder (1692 g), and the mixture was mixed in a tumbler mixer
(TM-15S, SHOWA KAGAKU KIKAI CO., LTD.) to give a mixed powder.
(3) The mixed powder was tableted by a rotary tableting
machine (AQUARIUS 2L, Kikusui Seisakusho Ltd.) by using a 4 mm¢
punch (tableting pressure: 4 kN, weight per tablet: 30 mg) to
give a core tablet with the following composition.
ition of ation (30 mg)
compound A 0.25 mg
D—mannitol (in granules) 21.2 mg
D~mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly atinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
W0 2012(099260
total 30 mg
Example 7
(1) D—mannitol (PEARLITOL 50C, Roquette) (450 g) was dissolved
in purified water (2550 g) to give a coating solution.
Compound A (150.5 g), D—mannitol (3068 g), microcrystalline
cellulose (CEOLUS , Asahi Kasei Corporation) (112.5 g),
and partly pregelatinized starch (PCS, Asahi Kasei
ation) (450 g) were uniformly mixed in a fluid bed dryer
granulator (FD-SS, POWREX CORPORATION), granulated while
spraying the coating solution (3000 g), and dried to give a
granulated powder. A part of the obtained granulated powder
was ground by a power mill grinding machine (P-3, SHOWA KAGAKU
KIKAI CO., LTD.) using a 1.5 mm¢ punching screen to give a
sieved powder.
(2) vidone (Kollidon CL—F, BASF) (90 g) and sodium
l fumarate (18 g) were added to the obtained sieved
powder (1692 g), and the e was mixed in a tumbler mixer
(TM-15$, SHOWA KAGAKU KIKAI CO., LTD.) to give a mixed powder.
(3) The mixed powder was tableted by a rotary tableting
machine (AQUARIUS 2L, i Seisakusho Ltd.) by using a 4 mm¢
punch (tableting pressure: 4 kN, weight per tablet: 30 mg) to
give a core tablet with the following composition.
Composition of preparation (30 mg)
compound A 1.0 mg
D—mannitol (in granules) 20.45 mg
D~mannitol (in coating layer) 3.0 mg
rystalline cellulose 0.75 mg
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
total 30 mg
Comparative Example 5
PCT/JPZOIZ/051279
(1) Hydroxypropylcellulose (HPC-L, NIPPON SODA CO., LTD.) (660
g) was dissolved in purified water (10230 g) to give a binding
solution. Compound A (1320 g), lactose (DMV INTERNATIONAL)
(16104 g), and corn starch (Japan Corn Starch CO., Ltd.) (2640
g) were uniformly mixed in a fluid bed dryer granulator (FD—$2,
POWREX CORPORATION), granulated while spraying the binding
solution (10890 g), and dried to give a granulated powder.
This granulation step was performed twice. A part of the
obtained granulated powder was ground by a power mill ng
machine (P~3, SHOWA KAGAKU KIKAI CO., LTD.) using a 1.5 mm¢
punching screen to give a sieved powder.
(2) Corn starch (1013 g) and magnesium stearate (298 g) were
added to the obtained sieved powder (37430 g), and the mixture
was mixed in a tumbler mixer (TM20—0—0, Suehiro Kakoki CO.,
Ltd.) to give a mixed powder.
(3) The mixed powder was tableted by a rotary tableting
machine IUS 36K, Kikusui Seisakusho Ltd.) by using a 7
mm¢ punch (tableting pressure: 7 kN, weight per tablet: 130 mg)
to give a tablet (core tablet).
(4) Hydroxypropylmethylcellulose (TC-5R, Shin—Etsu Chemical
Co., Ltd.) (1548 g) and Copovidone (310.5 g) were dissolved
and dispersed in purified water (16150 g) to give dispersion I.
Titanium oxide (207 g) and yellow ferric oxide (4.14 g) were
dispersed in purified water (1822 g) to give dispersion II.
Dispersion II was added to dispersion I, and the mixture was
stirred to give a g solution. Using a coater (High
Coater HCF~100N, Freund Corporation), the coating solution was
sprayed on the core tablet ed in (3) until the weight of
the core tablet increased by 5 mg per tablet to give a film—
coated tablet having the ing composition.
Composition of preparation (135 mg)
compound A 8.0 mg
lactose 97.6 mg
corn starch 19.4 mg
WO 2013099260
hydroxypropylcellulose 4.0 mg
magnesium stearate 1.0 mg
hydroxypropylmethylcellulose 3.74 mg
Copovidone 0.75 mg
titanium oxide 0.5 mg
yellow ferric oxide 0.01 mg
total 135 mg
Example 8
(1) D—Mannitol (PEARLITOL 50C, Roguette) (510 g) was dissolved
in purified water (2890 g) to give a coating solution.
nd A (17.05 g), D-mannitol (3114 g), microcrystalline
ose (CEOLUS PH-lOl, Asahi Kasei Corporation) (127.5 g),
and partly pregelatinized starch (PCS, Asahi Kasei
ation) (510 g) were uniformly mixed in a fluid bed dryer
granulator (FD—SS, POWREX CORPORATION), granulated while
spraying the coating solution (3400 g), and dried to give a
ated powder. A part of the obtained granulated powder
was sieved using a round sieve (mesh size 1.0 mm¢) to give
sieved powder A.
(2) The same step as (1) was performed to give sieved powder B.
(3) To the obtained sieved powder A (3146.5 g) and sieved
powder B (3146.5 g) were added crospovidone (Kollidon CL—F,
BASF) (375.0 g), aspartame (750 g), vanillin (7.5 g) and
sodium stearyl fumarate (75 g), and the mixture was mixed in a
tumbler mixer (TM-608, SHOWA KAGAKU KIKAI CO., LTD.) to give a
mixed powder.
(4) The mixed powder was tableted by a rotary tableting
machine IUS 2L, Kikusui Seisakusho Ltd.) using a 4 mm¢
punch (tableting pressure: 4 kN, weight per : 30 mg) to
give a core tablet with the following composition.
Composition of preparation (30 mg)
compound A 0.1 mg
D—mannitol (in granules) 18.32 mg
D-mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
aspartame 3.0 mg
vanillin 0.03 mg
total 30 mg
Example 9
(1) D—Mannitol (PEARLITOL 50C, te) (510 g) was dissolved
in purified water (2890 g) to give a coating solution.
Compound A (68.20 g), D—mannitol (3063 g), microcrystalline
cellulose (CEOLUS PH—lOl, Asahi Kasei Corporation) (127.5 g),
and partly pregelatinized starch (PCS, Asahi Kasei
ation) (510 g) were uniformly mixed in a fluid bed dryer
granulator (FD—SS, POWREX ATION), granulated while
spraying the coating solution (3400 g), and dried to give a
granulated powder. A part of the obtained granulated powder
was sieved by using a round sieve (mesh size 1.0 mm¢) to give
sieved powder A.
(2) The same step as (l) was performed to give sieved powder B.
(3) To the obtained sieved powder A (3146.5 g) and sieved
powder B (3146.5 g) were added crospovidone (Kollidon CL—F,
BASE) (375.0 g), aspartame (750 g), vanillin (7.5 g) and
sodium stearyl fumarate (75 g), and the e was mixed in a
r mixer (TM~6OS, SHOWA KAGAKU KIKAI CO., LTD.) to give a
mixed powder.
(4) The mixed powder was tableted by a rotary tableting
machine (AQUARIUS 2L, Kikusui Seisakusho Ltd.) using a 4 mm¢
punch (tableting pressure: 4 kN, weight per tablet: 30 mg) to
give a core tablet with the following composition.
Composition of preparation (30 mg)
compound A 0.4 mg
PCT/JPZOIZ/051279
D—mannitol (in granules) 18.02 mg
D—mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium stearyl fumarate 0.3 mg
aspartame 3.0 mg
vanillin 0.03 mg
total 30 mg
Example 10
(1) D—Mannitol (PEARLITOL 50C, Roquette) (510 g) was dissolved
in ed water (2890 g) to give a coating solution.
Compound A (136.4 g), D-mannitol (2995 g), microcrystalline
cellulose (CEOLUS PH-lOl, Asahi Kasei Corporation) (127.5 g),
and partly pregelatinized starch (PCS, Asahi Kasei
Corporation) (510 g) were uniformly mixed in a fluid bed dryer
granulator (FD-SS, POWREX CORPORATION), granulated while
spraying the coating solution (3400 g), and dried to give a
granulated powder. A part of the obtained granulated powder
was sieved by using a round sieve (mesh size 1.0 mm¢) to give
sieved powder A.
(2) The same step as (l) was med to give sieved powder B.
(3) To the ed sieved powder A (3146.5 g) and sieved
powder B (3146.5 g) were added crospovidone (Kollidon CL—F,
BASF) (375.0 g), ame (750 g), vanillin (7.5 g) and
sodium stearyl fumarate (75 g), and the mixture was mixed in a
tumbler mixer S, SHOWA KAGAKU KIKAI CO., LTD.) to give a
mixed powder.
(4) The mixed powder was tableted by a rotary tableting
machine lUS 2L, Kikusui Seisakusho Ltd.) using a 4 mm¢
punch (tableting pressure: 4 kN, weight per tablet: 30 mg) to
give a core tablet with the ing composition.
Composition of preparation (30 mg)
compound A 0.8 mg
D—mannitol (in granules) 17.62 mg
D—mannitol (in coating layer) 3.0 mg
microcrystalline cellulose 0.75 mg
partly pregelatinized starch 3.0 mg
crospovidone 1.5 mg
sodium.stearyl fumarate 0.3 mg
aspartame V3.0 mg
vanillin 0.03 mg
total 30 mg
Experimental Example 1
The tablet obtained in Example 1 was measured for the
tablet hardness and disintegration time. The tablet ss
was measured by a tablet hardness tester (TH—303MP, Toyama
Sangyo CO., LTD.) (n=lO). The disintegration time was measured
by a disintegration tester (CDT—101, Toyama Sangyo CO., LTD.)
(n=6). The results are shown in Table 1.
[0073}
disintegration tester conditions
rotation number: 50 rpm
plummet: 15 mm¢, (10 g)
Table 1
hardness
absolute hardness 2.73 N/mHF
disintegration
Experimental Example 2
The mixed powder ed in Example 1 was ed for
the dissolution property. The mixed powder (15 g)
sponding to 500 mg of compound A) was placed in the
Japanese copoeia 2nd fluid (500 ml), and the dissolution
property was evaluated by the Paddle Method, rotation number
rpm, 37°C. After adding the sample, the eluate was sampled
with time (0.25 min, 0.5 min, 0.75 min, 1 min, 5 min, 15 min,
min), filtered by using a hydrophilic filter (0.45 um),
dissolved by 10—fold diluting with the t
(water/acetonitrile mixed solution (1:1)), and quantified by
high performance liquid column chromatography (HPLC) under the
following conditions to calculate the solubility. The results
are shown in Table 2.
HPLC ions
detector: ultraviolet ray absorption spectrophotometer
measurement wavelength: 240 nm
column: YMC~Pack ODS—AM AM—307, 5 pm, inner diameter: 4.6 mm
: 75 mm
column temperature: 25°C
mobile phase: 0.01 mol/L phosphate buffer/acetonitrile mixed
solution (5:3)
flow: 1.2 ml/min
Table 2
compound A concentration (mg/ml)
1 0.237
0.273
Experimental Example 3
The injections obtained in Comparative Examples 1, 3,
oral tablets obtained in Comparative Examples 2, 4 and
ations for oral—mucosal absorption obtained in Examtfles
W0 2012f099260 PCT/320121051279
2 — 5 were measured for blood kinetics after intravenous
injection, oral, sublingual and buccal administrations in
Macaca fascicularis under g conditions. The plasma
tration before administration, and 5 min, 10 min, 20 min,
min, 60 min, 120 min, 240 min and 360 min after
administration was measured, and the area under the plasma
concentration time curve (AUC) was calculated according to the
trapezoidal rule. In addition, bioavailability (BA) was
determined by calculating the ratio of AUC by oral, sublingual
or buccal administration to AUC by intravenous injection. The
results are shown in Table 3.
PCT/JPZOlZ/051279
4mm 1 mé méw vdm I H.o HAW.“ o.mH oHN {thém
SE\C..nE.mE m
03. mdhmflmémmm .Nmflwém w.mmeo.maNH odmwfiodmma Némomfim.mmmmfi whmfimém m.mNHHHv.Nmom m.9536on m.mmNHHv.mmmv odmoafiodmmm
3635 m
x20 aéafivém H.936 m.mHm.NH m.mHH>.NN mdwwfifimom Néflmd mdafimdm .mflvém 923.3» Némflaém
.:35
an. m H.omHHo.NmH N.mTIro.vm odfifiodm wéflmfi o.mHHo.m mivfloéww .mv odaflodw .o.NHHo.mm
ummwnm QfiumummEOU Hmamfimxm «Sawmummaoo N N m m v m v m h
mamfimxm mamfimxm mamfimxm mbflumnmmfioo magnmxm mmaoo mamfimxm mHQdem mamfimxm 9Hng mamfimxm
floaumuumflcflfiom .
cofiwom coapom
mHEOH msoamhymuufin .mcfi ammo Hmsmcfiansm HMUUSQ msocmEmHunfl mg.” ammo HmstHHofim Hmoosnx-
m SE
magma 986 mmé H
PCTIJP2012/051279
Experimental Example 4
Oral preparation and ation for oral-mucosal
absorption were measured for blood kinetics of unchanged form
and activity metabolite M—II after oral or sublingual
administration to human. The plasma concentration before
administration, and 5 min, 10 min, 15 min, 20 min, 30 min, 45
min, 60 min, 90 min, 120 min, 180 min, 240 min, 360 min, 480
min, 600 min, 720 min and 1440 min after administration was
measured, and the area under the plasma concentration time
curve (AUC) was calculated according to the oidal rule.
The results are shown in Table 4.
PCT/JPZO12/051279
“27803 :E\CHE.05 w.hvmfiw.wmm H.>me.mNm o.hv>NH w.mmomH o.mmmfiw.omn
Aogulovuam :E\:HE.m5 o.mmem.qmm .mam o.mmvNH o.mmmva m.OmNHv.mmm
.III
x20 SEES: ma.mHm>.v Nm.Han.v N.mNHH.mw IIIIIIIIIIIIIIIIIIIIIS!Illlliilrllllllli 3.23;
Ao.omno.mv
Ea. ACHEV o.mv 8.0me52 o.mH 0.0m Ao.omaro.omv o.mv Ao.omlo.mav
GOHumummmum mbflumummfiou m m w m
mamamxm wamfimxm m>Humummfiou mamemxm 33mg
soapmuumflaflavm muse“ Hmuo HMdmcflHQSm HMHO Hanging
omen A95 w Illlilllllll m.o m m6
magma unmEmuSmmms mocmumnsm o:5 Snow m>..nu0.m wUflHonmpwE :1:
[0082}
Example 10
A methylcellulose powder (0.5 g) was dissolved in water
(99.5 g) under ice—cooling, and compound A (100 mg) was added
to the ed solution (10 ml), stirred and uniformly
dispersed therein. The obtained suspension was filled in a
spray device (spray amount: lOO e) to give an oral spray
ation.
Example 11
Hydroxypropyl—B—cyclodextrin (HP—B—CyD) (40 g) was
dissolved in water (60 g), and compound A (100 mg) was added
to the obtained solution (10 ml), stirred and dissolved
therein. The obtained solution was filled in a spray device
(spray amount: 100 uL/time) to give an oral spray preparation.
Example 12
Compound A (100 mg), polyvinylpyrrolidone (l g) and
hydroxypropylcellulose (18 g) were added to ethanol (100 ml)
and dissolved by stirring. The ed solution (1 ml) was
spread flat on a plastic sheet and dried to give an orally
rapidly dissolving film preparation.
Example 13
Compound A (100 mg), D—mannitol (5 g) and
bydroxypropylcellulose (100 mg) were added to a mixed on
(100 ml) of water and ethanol (4:1) and dissolved by stirring.
The obtained solution (1 ml) was dispensed to a pocket of a
blister pack with vinyl chloride resin as an inner film,
frozen at —30°C, and dried by a vacuum dryer to give an orally
rapidly ving freeze~dried preparation.
rial Applicability
The present invention can provide a novel preparation
showing improved bioavailability of a medicament and a
PCT/JPZOlZ/051279
production method f and the like.
When compound A is administered nasally (through nasal
mucosa) to a human subject, it is expected to be effective on
prophylaxis and/or treatment of bipolar disease as
administered oral—mucosally as disclosed above. Compound A can
be administered, for example, in the form of the ation
as disclosed in WO 01/15735.
When compound A is administerd to a human subject, it
can be also administered in the dosage forms suitable for
inhalation (e.g. nebulizer, etc) in order to prevent and/or
treat bipolar disease. The dosage forms can be produced
according to a general production method in this art. The dose
of compound A can be d referring to, for example, the
preparations (A) to (C) in the present application.
[0087]
This ation is based on patent application Nos.
2011—007371 and 27333 filed in Japan, the contents of
which are incorporated in full herein.
Claims (15)
1. Use of (S)—N—[2-(l,6,7,8—tetrahydro-2H-indeno[5,4—b]furan- 8-yl)ethyl]propionamide for the tion of a drug for the prophylaxis and/or treatment of a bipolar disorder in a human by oral—mucosal administration of (S)—N—[2—(l,6,7,8— ydro—ZH—indeno[5,4—b]furan—B—yl)ethyl]propionamide at
0.05 — 1.0 mg per day. 10 2. The use according to claim 1, n the oral—mucosal administration is sublingual administration or buccal administration.
3. The use according to claim 1, wherein the bipolar disorder 15 is bipolar disorder I.
4. The use according to claim 1, wherein the prophylaxis and/or treatment of a bipolar disorder is a treatment of a sion symptom associated with the bipolar disorder or 20 maintenance of a remission phase of the bipolar disorder.
5. The use according to claim 1, wherein the drug is a rapidly disintegrating preparation comprising es comprising said (S)—N—[2—(l,6,7,8—tetrahydro—2H—indeno[5,4—b]furan—8~ 25 yl)ethyl]propionamide coated with a coating layer containing sugar or sugar alcohol; and a disintegrant.
6. The use according to claim 5, wherein the granules further contains a binder.
7. The use according to claim 5, wherein the es further contains a masking agent.
8. The use ing to claim 5, wherein the granules further contains a solubilizer.
9. The use according to any one of claims 1 — 8, n the drug is a tablet.
10. A method of producing a rapidly disintegrating preparation, comprising a step of ing granules comprising (S)—N—[2— (l,6,7,8—tetrahydro—2H—indeno[5,4—b]furan—S— 10 yl)ethy1]propionamide, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules, and a step of mixing the coated granules with a disintegrant and molding the mixture, 15 wherein the rapidly disintegrating preparation is a drug for the prophylaxis and/or treatment of a bipolar disorder in a human by oral mucosal administration of 0.05 — 1.0 mg of (S)— N—[2—(1,6,7,8-tetrahydro—2H—indeno[5,4—b]furan yl)ethy1]propionamide per day.
11. The use according to claim 1, wherein the drug shows a higher ratio of an unchanged form and a lite of (S)-N— [2—(1,6,7,8—tetrahydro—2H—indeno[5,4—b]furan-B— yl)ethy1]propionamide after transfer into blood than that by 25 oral administration.
12. The use ing to claim 11, wherein the drug is a tablet. 3O
13. The use according to claim 11, wherein the drug is in the form of a film, troche, solution, sion, freeze-dried preparation, chewing gum or spray.
14. The use according to claim 1, substantially as herein described with reference to any one of the examples.
15. The method ing to claim 10, substantially as herein described with reference to any one of the examples.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-007371 | 2011-01-17 | ||
JP2011007371 | 2011-01-17 | ||
JP2011227333 | 2011-10-14 | ||
JP2011-227333 | 2011-10-14 | ||
PCT/JP2012/051279 WO2012099260A1 (en) | 2011-01-17 | 2012-01-16 | Orally dispersible tablet |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613265A NZ613265A (en) | 2015-08-28 |
NZ613265B2 true NZ613265B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012207818B2 (en) | Orally dispersible tablet | |
JP5053865B2 (en) | Method for producing orally disintegrating solid preparation | |
KR101612137B1 (en) | Orally disintegrating tablets | |
JP4740740B2 (en) | Drug-containing particles and solid preparation containing the particles | |
JP2016166230A (en) | Nalbuphine-containing formulations and uses thereof | |
CN112312912B (en) | Granules containing diamine derivatives | |
US8426461B2 (en) | Orally dispersible tablet | |
JP3899522B2 (en) | Formulation containing pranlukast hydrate with reduced bitterness | |
JP6061924B2 (en) | Oral dispersible formulation | |
NZ613265B2 (en) | Orally dispersible tablet | |
WO2018124282A1 (en) | Pharmaceutical composition and method for producing same | |
AU2013203069A1 (en) | Orally dispersible tablet | |
US20130060052A1 (en) | Orally dispersible tablet | |
EP3563847B1 (en) | Pharmaceutical composition | |
JP2005272458A (en) | Medical composition for oral administration | |
CN117653648A (en) | Pharmaceutical composition containing deuterated nucleoside compound and application of pharmaceutical composition in preparation of antiviral drugs | |
JP2006316051A (en) | Pranlukast hydrate-containing preparation having relieved bitterness |